Pradžia › B ląstelių leukemija
B ląstelių leukemija klinikiniai tyrimai JAV ieško dalyvių
17 tyrimai dėl B ląstelių leukemija ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Houston, TX7 tyrimai
- Washington, DC5 tyrimai
- Dallas, TX5 tyrimai
- Columbus, OH4 tyrimai
- Portland, OR4 tyrimai
- Philadelphia, PA3 tyrimai
- Spokane, WA3 tyrimai
- New York City, NY3 tyrimai
- Boston, MA3 tyrimai
- San Diego, CA3 tyrimai
- Charlotte, NC3 tyrimai
- Clifton, NJ3 tyrimai
- Louisville, KY3 tyrimai
- Pittsburgh, PA3 tyrimai
- Edison, NJ3 tyrimai
- Denver, CO3 tyrimai
- Chicago, IL3 tyrimai
Pagal valstiją
- Florida3 tyrimai
- Ilinoisas4 tyrimai
- Kalifornija7 tyrimai
- Kanzasas3 tyrimai
- Kentukis3 tyrimai
- Koloradas3 tyrimai
- Masčusetsas3 tyrimai
- Merilendas5 tyrimai
- Minesota3 tyrimai
- New Jersey4 tyrimai
- New York4 tyrimai
- North Carolina5 tyrimai
- Ohio7 tyrimai
- Oregon4 tyrimai
- Pennsylvania5 tyrimai
- Texas12 tyrimai
- Washington5 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT06542250CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Renkami dalyviai1/2 fazė
Amžius nuo 3 iki 39 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05442515Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-09-28 · NCT00923507Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Renkami dalyviai4 fazė
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06651970Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Renkami dalyviai1 fazė
Iki 75 metų · Visoms lytims · Atnaujinta 2026-09-16 · NCT06345027A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06564038Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Renkami dalyviai1 fazė
12 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-04 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Renkami dalyviai2 fazė
Amžius nuo 7 iki 25 · Visoms lytims · Atnaujinta 2026-08-19 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-11 · NCT07342478A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-31 · NCT06708897The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 95 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 1 iki 23 · Visoms lytims · Atnaujinta 2026-02-25 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-01-22 · NCT06357754Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.